ClinicalTrials.gg
CompletedNCT00413777TEMPO 2:4Updated Jul 2, 2017Results posted

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 2 interventional study of Tolvaptan in Polycystic Kidney, Autosomal Dominant, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
11th of 18
46 · median 91
Started
2005
the only one that year
Phase 2
7 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 11th largest by enrollment, is the only one that started in 2005, is one of 7 in phase 2, and was the 1st registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

This study's purpose is to evaluate the long-term safety of open-label tolvaptan regimens to determine the maximally-tolerated dose and acquire pilot efficacy data in patients with autosomal dominant polycystic kidney disease (ADPKD).

Read the detailed description

Autosomal Dominant Polycystic Kidney Disease is a genetic disease classified by the formation of fluid-filled cysts in the kidneys. The accumulation of these cysts causes the kidneys to enlarge several times the normal size and leads to the eventual loss of renal function and ultimately results in renal failure in end-stage patients. This is a disease with life-threatening implications to those who have it, and their family members who may also be affected. Aside from early anti-hypertensive control and dietary protein restriction, which are presumed to offer a modest degree of protection, most surviving patients require renal replacement therapy (dialysis and transplant) and suffer from high morbidity and mortality.

A rationale for use of tolvaptan in these genetic disorders has been proven, in principle, through use of a variety of animal models. In these models, tolvaptan is effective in halting or reversing the progression of this renal disease.

The current study is being undertaken in order to evaluate whether tolvaptan, an oral vasopressin V2 receptor inhibitor, will maintain an adequate safety profile and show a potential clinical benefit by reducing total renal volume in the hopes of making an impact upon disease progression.

03

Conditions studied

  • Polycystic Kidney, Autosomal Dominant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior participation in designated tolvaptan ADPKD studies (156-04-248, 156-04-249).
  • Able to give .

Exclusion criteria

Exclusion Criteria:

  • Women who are breast feeding and females of who are not using acceptable methods.
  • In the opinion of the study investigator or sponsor may present a safety risk.
  • Patients who are unlikely to adequately comply with study procedures.
  • Patients who at Day 1 have an estimated (GFR) below 30 mL/min or who anticipate renal-replacement therapy within one year of study entry.
  • Patients having to magnetic resonance imaging (MRI) or gadolinium contrast will be eligible but will not be able to participate in MRI.
  • Patients taking a diuretic within 1 week of enrollment or likely to need diuretic therapy prior to Month 2.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Tolvaptan 45/15 mg/day orally for up to 4 years

    Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.

    Drug: Tolvaptan

  • Experimental
    Tolvaptan 60/30 mg/day orally for up to 4 years

    Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.

    Drug: Tolvaptan

Interventions

  • Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.

    Also known as: OPC-41061

06

What researchers measure

Primary outcomes

  1. Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion.

    An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in a study , whether or not it was considered drug-related by the study physician. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study drug treatment; or if the event was continuous from Baseline and was serious, study drug related, or resulted in death, discontinuation.

    Time frame: AEs were recorded from screening (ICF was signed) until 7-Day follow-up

Secondary outcomes

  1. Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose.

    Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.

    Time frame: Baseline to Month 36

  2. Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose.

    Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

    Time frame: Baseline to Month 24

  3. Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime.

    Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

    Time frame: Baseline to Month 24

  4. Percent Change From Baseline in Renal Volume.

    Total Kidney Volume (TKV) was assessed by the central magnetic resonance imaging (MRI) rater.

    Time frame: Baseline to Month 36

  5. Change From Pre-dose Baseline in Renal Function Estimated by Glomerular Filtration Rate (GFR).

    GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.

    Time frame: Baseline to Month 36

  6. Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose- Extension.

    Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36, Extension Day 1, and Extension Month 12 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.

    Time frame: Baseline to Months 2, 6, 12, 24, 36, Extension Day 1, Extension Month 12

  7. Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose- Extension.

    Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

    Time frame: Baseline to Month 24

  8. Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime- Extension.

    Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

    Time frame: Baseline to Month 24

  9. Percent Change From Baseline in Renal Volume-Extension.

    TKV was assessed by the central magnetic resonance imaging (MRI) rater.

    Time frame: Baseline to Months 2, 12, 24, 36, Extension Day 1, Extension Month 12

  10. Change From Pre-dose Baseline in Renal Function Estimated by GFR- Extension.

    GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.

    Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 12

  11. Mean Change From Baseline in Systolic Blood Pressure (sBP) for Hypertension Assessment.

    The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

    Time frame: Baseline to Month 36

  12. Mean Change From Baseline in Diastolic Blood Pressure (dBP) for Hypertension Assessment.

    The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

    Time frame: Baseline to Month 36

  13. Mean Change From Baseline in Mean Arterial Pressure (MAP) for Hypertension Assessment.

    The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

    Time frame: Baseline to Month 36

  14. Mean Change From Baseline in sBP for Hypertension Assessment- Extension.

    The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

    Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12

  15. Mean Change From Baseline in dBP for Hypertension Assessment- Extension.

    The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

    Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12

  16. Mean Change From Baseline in MAP for Hypertension Assessment- Extension.

    The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

    Time frame: Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12

  17. Mean Change From Baseline in Patient-assessed Renal Pain Scale.

    Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.

    Time frame: Baseline to Month 36

  18. Mean Change From Baseline in Patient-assessed Renal Pain Scale- Extension.

    Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.

    Time frame: Baseline to Months 2, 6, 12, 24, 36, Extension Day 1, Extension Month 12

  19. Mean Change From Baseline in Abdominal Girth Measurement.

    The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).

    Time frame: Baseline to Month 36

  20. Mean Change From Baseline in Abdominal Girth Measurement- Extension.

    The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).

    Time frame: Baseline to Extension Day 1, Extension Month 12

07

Results

Posted Jul 2, 2017

Participant flow

A phase 2, multi-center, open-label trial, to determine the safety, tolerability, and efficacy study of split-dose oral regimens of tolvaptan tablets in a range of 30 to 120 mg/d in autosomal dominant polycystic kidney disease (ADPKD) participants.

Fixed-dose Period
Participant flow — Fixed-dose Period
MilestoneTolvaptan 45+15 mgTolvaptan 60+30 mg
Started2224
Completed1821
Not completed43
Withdrew: Lost to follow-up11
Withdrew: Adverse event21
Withdrew: Met withdrawal criteria10
Withdrew: Withdrew consent01
Extension Period
Participant flow — Extension Period
MilestoneTolvaptan 45+15 mgTolvaptan 60+30 mg
Started1718
Completed1718
Not completed00

Outcome measures

PrimarySafety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion.

An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in a study , whether or not it was considered drug-related by the study physician. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study drug treatment; or if the event was continuous from Baseline and was serious, study drug related, or resulted in death, discontinuation.

Time frame:
AEs were recorded from screening (ICF was signed) until 7-Day follow-up
Reported as:
Number · participants
Safety Assessments Based on Vital Signs, Electrocardiogram (ECG's), Clinical Laboratory Tests, Physical Examinations Are Reported as Adverse Events (AEs) Upon Study Physician Discretion.
participantsTolvaptan 45+15 mgTolvaptan 60+30 mg
Participants with serious TEAEs38
Participants with severe TEAEs610
Participants discontinued due to AEs31
SecondaryMean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose.

Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.

Time frame:
Baseline to Month 36
Reported as:
Mean · mOsm/kg
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose.
mOsm/kgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 21, 22)-274.10 ± 223.14-228.00 ± 238.19
Month 6 (N= 19, 23)-288.42 ± 219.55-263.78 ± 221.05
Month 12 (N= 17, 21)-227.29 ± 226.63-178.43 ± 228.43
Month 24 (N= 18, 20)-170.17 ± 272.21-189.75 ± 229.33
Month 36 (N= 18, 21)-222.50 ± 229.91-208.90 ± 194.19
SecondaryMean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose.

Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

Time frame:
Baseline to Month 24
Reported as:
Mean · mOsm/kg
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose.
mOsm/kgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 21, 21)-263.95 ± 220.40-298.71 ± 257.53
Month 6 (N= 19, 23)-321.78 ± 242.53-294.13 ± 215.95
Month 12 (N= 16, 20)-288.20 ± 216.85-234.65 ± 238.82
Month 24 (N= 1, 7)-405.00 ± NA-227.14 ± 334.13
SecondaryMean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime.

Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

Time frame:
Baseline to Month 24
Reported as:
Mean · mOsm/kg
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime.
mOsm/kgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 21, 22)-275.00 ± 219.37-291.09 ± 194.88
Month 6 (N= 19, 23)-327.41 ± 217.15-301.83 ± 210.55
Month 12 (16, 18)-283.21 ± 230.81-245.83 ± 234.46
Month 24 (N= 1, 7)-263.00 ± NA-246.00 ± 208.50
SecondaryPercent Change From Baseline in Renal Volume.

Total Kidney Volume (TKV) was assessed by the central magnetic resonance imaging (MRI) rater.

Time frame:
Baseline to Month 36
Reported as:
Mean · Percentage change per month
Percent Change From Baseline in Renal Volume.
Percentage change per monthTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 21, 24)-1.0 ± 5.2-1.3 ± 5.3
Month 12 (N= 18, 22)0.3 ± 6.02.4 ± 6.6
Month 24 (N= 18, 21)4.6 ± 8.41.0 ± 8.3
Month 36 (N= 18, 20)9.9 ± 11.85.3 ± 10.0
SecondaryChange From Pre-dose Baseline in Renal Function Estimated by Glomerular Filtration Rate (GFR).

GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.

Time frame:
Baseline to Month 36
Reported as:
Mean · dL/mg
Change From Pre-dose Baseline in Renal Function Estimated by Glomerular Filtration Rate (GFR).
dL/mgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 22, 24)-0.09 ± 0.11-0.05 ± 0.13
Month 6 (N= 19, 21)-0.03 ± 0.10-0.01 ± 0.12
Month 9 (N= 18, 23)-0.01 ± 0.12-0.03 ± 0.13
Month 12 (N= 17, 22)-0.03 ± 0.11-0.01 ± 0.18
Month 16 (N= 18, 21)-0.06 ± 0.12-0.02 ± 0.12
Month 20 (N= 18, 21)-0.06 ± 0.10-0.03 ± 0.15
Month 24 (N= 18, 20)-0.04 ± 0.10-0.02 ± 0.13
Month 28 (N= 18, 21)-0.07 ± 0.10-0.02 ± 0.14
Month 32 (N= 18, 21)-0.09 ± 0.14-0.06 ± 0.12
Month 36 (N= 18, 21)-0.07 ± 0.11-0.06 ± 0.13
SecondaryMean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose- Extension.

Spot urine osmolality at trough was determined for urine samples collected immediately prior to morning dosing for Day 1 (Baseline), Months 2, 6, 12, 24, 36, Extension Day 1, and Extension Month 12 for all participants. Sample was taken after the first morning's void and was provided as a mid-stream, clean catch sample. During the titration period (Weeks 1, 2, 3 and 4) and at Month 6, additional samples were collected for the preceding day immediately preceding the 2nd daily dose and at bed-time. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration. At the Month 36 visit, participants were given a urine container and brought back the specimen at Extension Day 1. All participants were fasting.

Time frame:
Baseline to Months 2, 6, 12, 24, 36, Extension Day 1, Extension Month 12
Reported as:
Mean · mOsm/kg
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to First Daily Dose- Extension.
mOsm/kgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 17)-328.06 ± 207.05-176.88 ± 225.54
Month 6 (N= 17, 18)-270.94 ± 200.29-223.50 ± 211.61
Month 12 (N= 16, 17)-234.56 ± 232.01-155.65 ± 242.53
Month 24 (N= 17, 17)-164.06 ± 279.32-160.06 ± 196.50
Month 36 (N= 17, 18)-234.71 ± 230.90-196.33 ± 175.23
Extension Day 1 (N= 17, 17)-54.59 ± 236.96-157.18 ± 229.19
Extension Month 12 (N= 17, 18)-115.59 ± 278.19-202.44 ± 227.92
SecondaryMean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose- Extension.

Urine osmolality at steady state (after at least 4 days of dosing) including "absolute trough" prior to the second daily dose. Samples for this assessment were taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day immediately preceding the second daily dose. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

Time frame:
Baseline to Month 24
Reported as:
Mean · mOsm/kg
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Second Daily Dose- Extension.
mOsm/kgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 17)-281.63 ± 235.90-254.82 ± 217.14
Month 6 (N= 17, 18)-305.25 ± 223.90-261.61 ± 201.49
Month 12 (N= 16, 16)-288.20 ± 216.85-190.69 ± 201.16
Month 24 (N= 1, 6)-405.00 ± NA-120.50 ± 196.05
SecondaryMean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime- Extension.

Urine osmolality at steady state (after at least 4 days of dosing) including "average of troughs" (the mean urine osmolality prior to bedtime). Samples for this assessment were to be taken as closely coincident to PK blood sample as practical. During Weeks 1, 2, 3 and 4 of the Titration Period and at Month 6, additional samples were collected for the preceding day at bedtime. These samples allowed derivation of an average nadir of spot urine osmolality concentrations at each dose level and while at steady state during extended tolvaptan administration.

Time frame:
Baseline to Month 24
Reported as:
Mean · mOsm/kg
Mean Change From Baseline in Trough Urine Osmolality at Steady State Prior to Bedtime- Extension.
mOsm/kgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 17)-322.27 ± 207.32-258.88 ± 174.51
Month 6 (N= 17, 18)-309.73 ± 225.40-264.50 ± 180.12
Month 12 (16, 15)-283.21 ± 230.81-206.00 ± 200.36
Month 24 (N= 1, 6)-263.00 ± NA-187.50 ± 153.04
SecondaryPercent Change From Baseline in Renal Volume-Extension.

TKV was assessed by the central magnetic resonance imaging (MRI) rater.

Time frame:
Baseline to Months 2, 12, 24, 36, Extension Day 1, Extension Month 12
Reported as:
Mean · Percentage change per month
Percent Change From Baseline in Renal Volume-Extension.
Percentage change per monthTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 18)-1.3 ± 5.4-1.4 ± 3.9
Month 12 (N= 17, 18)-0.7 ± 4.51.9 ± 5.7
Month 24 (N= 17, 18)3.2 ± 6.00.2 ± 7.2
Month 36 (N= 17, 18)7.9 ± 8.73.8 ± 7.4
Extension Day 1 (N= 17, 18)14.1 ± 10.58.4 ± 7.9
Extension Month 12 (N= 17, 18)15.7 ± 12.710.7 ± 10.4
SecondaryChange From Pre-dose Baseline in Renal Function Estimated by GFR- Extension.

GFR was estimated using reciprocal serum creatinine formula. The formula does not adjust for body weight or height, but this may be done to normalize to body surface area. The formula for reciprocal Serum creatinine is: 1/Pcr. (Pcr = serum creatinine concentration \[mg/dL\]). Clinic weight scales were calibrated at least yearly.

Time frame:
Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 12
Reported as:
Mean · dL/mg
Change From Pre-dose Baseline in Renal Function Estimated by GFR- Extension.
dL/mgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 18)-0.09 ± 0.11-0.04 ± 0.15
Month 6 (N= 17, 16)-0.03 ± 0.11-0.00 ± 0.13
Month 9 (N= 16, 18)-0.01 ± 0.11-0.01 ± 0.14
Month 12 (N= 16, 17)-0.03 ± 0.12-0.00 ± 0.21
Month 16 (N= 17, 16)-0.06 ± 0.12-0.01 ± 0.13
Month 20 (N= 17, 18)-0.06 ± 0.10-0.02 ± 0.16
Month 24 (N= 17, 17)-0.04 ± 0.11-0.02 ± 0.14
Month 28 (N= 17, 18)-0.06 ± 0.10-0.02 ± 0.14
Month 32 (N= 17, 18)-0.09 ± 0.14-0.05 ± 0.12
Month 36 (N= 17, 18)-0.07 ± 0.11-0.05 ± 0.14
Extension Day 1 (N= 17, 18)-0.04 ± 0.13-0.01 ± 0.17
Extension Month 12 (N= 17, 18)-0.05 ± 0.17-0.04 ± 0.14
SecondaryMean Change From Baseline in Systolic Blood Pressure (sBP) for Hypertension Assessment.

The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

Time frame:
Baseline to Month 36
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic Blood Pressure (sBP) for Hypertension Assessment.
mmHgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 22, 24)-3.2 ± 12.6-3.0 ± 15.4
Month 6 (N= 19, 23)-3.6 ± 10.8-5.0 ± 12.4
Month 9 (N= 18, 23)-4.6 ± 12.5-3.5 ± 12.5
Month 12 (N= 18, 23)-8.0 ± 14.6-3.5 ± 14.2
Month 16 (N= 18, 23)-6.2 ± 14.2-2.9 ± 12.6
Month 20 (N= 18, 21)-7.9 ± 11.4-10.0 ± 16.4
Month 24 (N= 18, 21)-2.1 ± 18.4-0.1 ± 14.7
Month 28 (N= 18, 21)-4.7 ± 14.2-4.1 ± 17.1
Month 32 (N= 18, 21)-7.3 ± 10.9-7.2 ± 14.8
Month 36 (N= 18, 21)-0.2 ± 13.2-5.4 ± 17.6
SecondaryMean Change From Baseline in Diastolic Blood Pressure (dBP) for Hypertension Assessment.

The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

Time frame:
Baseline to Month 36
Reported as:
Mean · mmHg
Mean Change From Baseline in Diastolic Blood Pressure (dBP) for Hypertension Assessment.
mmHgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 22, 24)-4.0 ± 11.4-0.2 ± 9.8
Month 6 (N= 19, 23)-3.6 ± 8.2-2.5 ± 11.2
Month 9 (N= 18, 23)-4.8 ± 8.9-2.8 ± 11.4
Month 12 (N= 17, 23)-9.2 ± 12.6-1.1 ± 12.6
Month 16 (N= 18, 23)-5.6 ± 11.4-2.3 ± 10.7
Month 20 (N= 18, 21)-7.4 ± 9.8-5.6 ± 12.1
Month 24 (N= 18, 21)-3.1 ± 11.6-0.1 ± 12.4
Month 28 (N= 18, 21)-5.3 ± 10.6-2.2 ± 8.8
Month 32 (N= 18, 21)-4.6 ± 11.2-3.0 ± 10.9
Month 36 (N= 18, 21)-5.4 ± 10.0-4.0 ± 13.2
SecondaryMean Change From Baseline in Mean Arterial Pressure (MAP) for Hypertension Assessment.

The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

Time frame:
Baseline to Month 36
Reported as:
Mean · mmHg
Mean Change From Baseline in Mean Arterial Pressure (MAP) for Hypertension Assessment.
mmHgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 22, 24)-3.7 ± 10.5-1.0 ± 10.5
Month 6 (N= 19, 23)-3.6 ± 7.4-3.3 ± 11.1
Month 9 (N= 18, 23)-4.7 ± 9.2-3.0 ± 10.8
Month 12 (N= 18, 23)-12.0 ± 18.9-1.8 ± 12.1
Month 16 (N= 18, 23)-5.8 ± 11.0-2.5 ± 10.6
Month 20 (N= 18, 21)-7.6 ± 9.7-7.0 ± 12.3
Month 24 (N= 18, 21)-2.7 ± 13.0-0.1 ± 12.0
Month 28 (N= 18, 21)-5.2 ± 11.2-2.7 ± 10.1
Month 32 (N= 18, 21)-5.6 ± 10.0-4.3 ± 11.2
Month 36 (N= 18, 21)-3.8 ± 9.6-4.4 ± 13.8
SecondaryMean Change From Baseline in sBP for Hypertension Assessment- Extension.

The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

Time frame:
Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12
Reported as:
Mean · mmHg
Mean Change From Baseline in sBP for Hypertension Assessment- Extension.
mmHgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 18)-1.6 ± 13.0-2.7 ± 15.0
Month 6 (N= 17, 18)-3.4 ± 11.4-5.6 ± 13.7
Month 9 (N= 16, 18)-4.1 ± 13.2-4.3 ± 13.7
Month 12 (N= 17, 18)-8.9 ± 14.5-3.3 ± 15.5
Month 16 (N= 17, 18)-6.5 ± 14.5-1.7 ± 13.9
Month 20 (N= 17, 18)-7.7 ± 11.7-9.3 ± 17.1
Month 24 (N= 17, 18)-1.8 ± 18.91.4 ± 15.2
Month 28 (N= 17, 18)-4.9 ± 14.6-3.4 ± 17.7
Month 32 (N= 17, 18)-7.6 ± 11.1-6.8 ± 16.0
Month 36 (N= 17, 18)-0.6 ± 13.5-5.4 ± 18.8
Extension Day 1 (N= 17, 18)-4.4 ± 11.8-5.1 ± 14.9
Extension Month 4 (N= 17, 18)-1.1 ± 16.1-8.7 ± 11.8
Extension Month 8 (N= 17, 18)1.8 ± 13.1-7.3 ± 14.8
Extension Month 12 (N= 17, 18)-0.5 ± 13.5-7.1 ± 12.2
SecondaryMean Change From Baseline in dBP for Hypertension Assessment- Extension.

The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

Time frame:
Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12
Reported as:
Mean · mmHg
Mean Change From Baseline in dBP for Hypertension Assessment- Extension.
mmHgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 18)-5.5 ± 12.40.3 ± 9.7
Month 6 (N= 17, 18)-4.5 ± 8.2-2.4 ± 12.6
Month 9 (N= 16, 18)-5.3 ± 9.4-2.9 ± 11.8
Month 12 (N= 16, 18)-10.1 ± 12.4-1.9 ± 13.0
Month 16 (N= 17, 18)-6.9 ± 10.1-2.1 ± 12.0
Month 20 (N= 17, 18)-7.5 ± 10.0-6.1 ± 12.1
Month 24 (N= 17, 18)-3.9 ± 11.4-0.6 ± 12.7
Month 28 (N= 17, 18)-5.6 ± 10.8-2.9 ± 8.4
Month 32 (N= 17, 18)-5.4 ± 11.0-3.6 ± 11.4
Month 36 (N= 17, 18)-5.7 ± 10.2-4.8 ± 14.0
Extension Day 1 (N= 17, 18)-7.9 ± 7.3-4.0 ± 10.8
Extension Month 4 (N= 17, 18)-6.8 ± 10.6-6.1 ± 10.8
Extension Month 8 (N= 17, 18)-5.0 ± 7.9-6.7 ± 12.7
Extension Month 12 (N= 17, 18)-6.0 ± 8.9-5.6 ± 11.7
SecondaryMean Change From Baseline in MAP for Hypertension Assessment- Extension.

The participants were seated and resting systolic and diastolic BP for each scheduled assessment was recorded. At each assessment, participants were categorized (based on repeated blood pressure measurements as being normotensive (MAP \< 100 mm Hg and off therapy), high normal (sBP \> 129 and or dBP \> 84 mm Hg off therapy) or hypertensive (sBP \>140 and/or dBP \> 90 mm Hg). The mean arterial pressure (MAP) was derived from these values and were not recorded (MAP = diastolic pressure + \[1/3 x pulse pressure (ie systolic - diastolic pressure)\] in mm Hg).

Time frame:
Baseline to Months 2, 6, 9, 12, 16, 20, 24, 28, 32, 36, Extension Day 1, Extension Month 4, Extension Month 8, Extension Month 12
Reported as:
Mean · mmHg
Mean Change From Baseline in MAP for Hypertension Assessment- Extension.
mmHgTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 18)-4.1 ± 11.6-0.6 ± 10.0
Month 6 (N= 17, 18)-4.2 ± 7.7-3.4 ± 12.5
Month 9 (N= 16, 18)-4.8 ± 9.8-3.4 ± 11.5
Month 12 (N= 17, 18)-13.1 ± 18.9-2.3 ± 12.9
Month 16 (N= 17, 18)-6.8 ± 10.4-1.9 ± 11.8
Month 20 (N= 17, 18)-7.5 ± 10.0-7.2 ± 12.8
Month 24 (N= 17, 18)-3.1 ± 13.20.1 ± 12.6
Month 28 (N= 17, 18)-5.5 ± 11.4-2.9 ± 10.2
Month 32 (N= 17, 18)-6.2 ± 10.0-4.6 ± 12.0
Month 36 (N= 17, 18)-4.1 ± 9.8-5.1 ± 14.8
Extension Day 1 (N= 17, 18)-6.8 ± 7.8-4.4 ± 11.0
Extension Month 4 (N= 17, 18)-5.1 ± 10.7-6.9 ± 10.1
Extension Month 8 (N= 17, 18)-2.8 ± 8.6-6.8 ± 12.1
Extension Month 12 (N= 17, 18)-4.2 ± 9.3-6.0 ± 10.9
SecondaryMean Change From Baseline in Patient-assessed Renal Pain Scale.

Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.

Time frame:
Baseline to Month 36
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Patient-assessed Renal Pain Scale.
Units on a scaleTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 22, 24)0.6 ± 3.10.0 ± 1.6
Month 6 (N= 19, 23)0.4 ± 2.8-0.1 ± 1.7
Month 12 (N= 18, 23)1.2 ± 3.3-0.1 ± 2.1
Month 24 (N= 18, 21)0.2 ± 1.61.0 ± 3.3
Month 36 (N= 18, 21)0.6 ± 2.30.5 ± 2.2
SecondaryMean Change From Baseline in Patient-assessed Renal Pain Scale- Extension.

Participants were asked the question to assess the relative level of pain attributed to their kidneys. This question was, "On a scale of 0 to 10, with zero represented no pain at all and 10 represented the worst pain ever experienced, what was the worst kidney pain experienced in the last 4 months?" If the latest assessment was less than 4 months prior, the question was substituted "since your last visit" for "in the last 4 months". The same interrogator designated to this task was used throughout the study for each participant.

Time frame:
Baseline to Months 2, 6, 12, 24, 36, Extension Day 1, Extension Month 12
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Patient-assessed Renal Pain Scale- Extension.
Units on a scaleTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 18)0.9 ± 2.70.3 ± 1.3
Month 6 (N=17, 18)0.8 ± 2.5-0.2 ± 1.9
Month 12 (N= 17, 18)1.2 ± 3.4-0.3 ± 2.0
Month 24 (N= 17, 18)0.2 ± 1.60.8 ± 3.3
Month 36 (N= 17, 18)0.6 ± 2.30.5 ± 2.4
Extension Day 1 (N= 17, 18)-0.3 ± 0.60.8 ± 2.1
Extension Month 12 (N= 17, 18)-0.4 ± 1.3-0.6 ± 2.2
SecondaryMean Change From Baseline in Abdominal Girth Measurement.

The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).

Time frame:
Baseline to Month 36
Reported as:
Mean · cm
Mean Change From Baseline in Abdominal Girth Measurement.
cmTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 22, 24)0.6 ± 5.0-2.3 ± 6.1
Month 6 (N= 18, 23)1.4 ± 6.50.5 ± 4.6
Month 12 (N= 18, 23)1.3 ± 4.7-2.8 ± 11.5
Month 24 (N= 17, 21)2.0 ± 7.4-0.6 ± 6.7
Month 36 (N= 18, 21)3.1 ± 7.20.3 ± 7.3
SecondaryMean Change From Baseline in Abdominal Girth Measurement- Extension.

The participant had a measurement of their abdominal girth recorded. The measurement will be taken with a tape measure extending around the abdomen at the level of the iliac crests laterally and the umbilicus anteriorly. The examiner should also palpate for each kidney and liver edge, noting presence or enlargement. (By definition if the kidneys are palpable they are enlarged, the liver edge may be palpable but not enlarged).

Time frame:
Baseline to Extension Day 1, Extension Month 12
Reported as:
Mean · cm
Mean Change From Baseline in Abdominal Girth Measurement- Extension.
cmTolvaptan 45+15 mgTolvaptan 60+30 mg
Month 2 (N= 17, 18)-0.8 ± 3.9-2.8 ± 7.0
Month 6 (N= 16, 18)0.3 ± 5.60.3 ± 5.1
Month 12 (N= 17, 18)1.1 ± 4.8-3.5 ± 12.9
Month 24 (N= 17, 21)2.0 ± 7.4-1.1 ± 7.1
Month 36 (N= 17, 18)2.5 ± 6.90.1 ± 7.7
Extension Day 1 (N= 17, 18)4.2 ± 7.22.9 ± 7.9
Extension Month 12 (N= 17, 18)4.6 ± 9.51.6 ± 6.1

Adverse events

Collected over AEs were recorded from screening (ICF was signed) until 7-days of safety follow-up. Participants with AEs in multiple system organ classes were counted only once towards the total.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan 45+15 mg—3/22 (13.6%)20/22 (90.9%)
Tolvaptan 60+30 mg—8/24 (33.3%)23/24 (95.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventTolvaptan 45+15 mgTolvaptan 60+30 mg
Atrial fibrillationCardiac disorders0/222/24
CholelithiasisHepatobiliary disorders1/220/24
Pituitary tumor benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/220/24
Renal painRenal and urinary disorders1/221/24
TachycardiaCardiac disorders0/221/24
Polycystic liver diseaseCongenital, familial and genetic disorders0/221/24
Abdominal painGastrointestinal disorders0/221/24
Epiploic appendagitisGastrointestinal disorders0/221/24
Chest painGeneral disorders0/221/24
PyelonephritisInfections and infestations0/221/24
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTolvaptan 45+15 mgTolvaptan 60+30 mg
Renal painRenal and urinary disorders9/229/24
DizzinessNervous system disorders6/223/24
PolyuriaRenal and urinary disorders6/222/24
Upper respiratory tract infectionInfections and infestations1/226/24
Urinary tract infectionInfections and infestations1/226/24
NocturiaRenal and urinary disorders5/222/24
Abdominal painGastrointestinal disorders2/225/24
FatigueGeneral disorders4/225/24
ThirstGeneral disorders1/225/24
Back painMusculoskeletal and connective tissue disorders4/223/24

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tolvaptan 45+15 mgTolvaptan 60+30 mgTotal
Mean39.3 ± 8.443.9 ± 7.841.7 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan 45+15 mgTolvaptan 60+30 mgTotal
Female161834
Male6612
08

Study locations

11 sites
  • University of Colorado
    Denver, Colorado, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida, United States
  • Emory University School of Medicine
    Atlanta, Georgia, United States
  • Univerisity of Kansas Medical Center
    Kansas City, Kansas, United States
  • Johns Hopkins School of Medicine
    Baltimore, Maryland, United States
  • Davita Clinical Research
    Minneapolis, Minnesota, United States
  • Mayo Medical Center
    Rochester, Minnesota, United States
  • Rogosin Institute
    New York, New York, United States
  • Northwest Renal Clinic
    Portland, Oregon, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
  • Nephrology Clinical Research Center at the University of Virginia
    Charlottesville, Virginia, United States
09

References and documents

Publications

  • Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003 Oct;9(10):1323-6. doi: 10.1038/nm935. Epub 2003 Sep 21. PubMed 14502283 ↗
  • Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004 Apr;10(4):363-4. doi: 10.1038/nm1004. Epub 2004 Feb 29. PubMed 14991049 ↗
  • Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8. PubMed 21903984 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 7 years 1 month after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2006
First posted
Dec 20, 2006
Start
Dec 2005
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results delay requested
May 22, 2012
Results first posted
Jul 2, 2017
Last update
Jul 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00413777
Responsible party
Sponsor
First posted
Dec 20, 2006
Start date
Dec 2005
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Jul 2, 2017
Last update
Jul 2, 2017

Study contacts

Vicente Torres, MD, PhD
principal investigator · Mayo Medical Center
Frank Czerweic, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion